**Notice:** It is not appropriate to bill Medicare for services that are not
covered (as described by this entire LCD) as if they are covered. When billing
for non-covered services, use the appropriate modifier.  
  
Compliance with the provisions in this policy may be monitored and addressed
through post payment data analysis and subsequent medical review audits.  
  
 **History/Background and/or General Information**  
  
The full field electroretinogram (ERG) is used to detect loss of retinal
function or distinguish between retinal and optic nerve lesions. ERG measures
the electrical activity generated by neural and non-neuronal cells in the
retina in response to a light stimulus. ERGs are usually obtained using
electrodes embedded in a corneal contact lens, or a thin wire inside the lower
eyelid, which measure a summation of retinal electrical activity at the
corneal surface. The International Society for Clinical Electrophysiology of
Vision (ISCEV) introduced minimum standards for the ERG in 1989. The ERG helps
to distinguish retinal degeneration and dystrophies. The focal or foveal ERG
(fERG) is useful in providing information regarding diseases limited to the
macula. Multi-focal electroretinography (mfERG) is a higher resolution form of
ERG, enabling assessment of ERG activity in small areas of the retina. Pattern
ERG (PERG) uses pattern-reversal stimuli and is used to detect subtle optic
neuropathies.  
  
 **ERG in Glaucoma**  
  
A 2011 report by the American Academy of Ophthalmology (AAO) on "Assessment of
Visual Function in Glaucoma" noted that while ERG, as objective measures of
visual function, provided testing free of patient input, issues prevent their
adoption for glaucoma management. It concluded that advances in technology
have yet to produce definitive guidance on the diagnosis of glaucoma or its
progression over time and that further research on an objective measure of
visual function is needed.  
  
Since then several studies have investigated the use of ERG technology to
differentiate between normal healthy eyes and eyes with early to advanced
visual field loss resulting from glaucoma. The authors indicated that ERG may
allow earlier diagnosis of glaucoma. However, Novitas has determined that
without larger studies, AAO's 2011 conclusion, that ERG's have yet to produce
definitive guidance on the diagnosis of glaucoma or its progression over time,
remains. This was also the conclusion of a 2013 study which prospectively
monitored progressive changes of RGC function in early glaucoma using PERG.
The authors concluded that further follow-up is required to determine whether
PERG losses are predictors of future visual field loss.  
  
Neither of the 2015 AAO Preferred Practice Guidelines, "Primary Open-Angle
Glaucoma Suspect" or "Primary Open-Angle Glaucoma," mention ERG as a
diagnostic tool.  
  
There remain no verified guidelines for normal vs. abnormal that would be
easily applicable to an individual patient. Novitas, therefore, considers the
use of ERG for either glaucoma diagnosis or management investigational.  
  
 **Covered Indications**

  1. To diagnose loss of retinal function or distinguish between retinal lesions and optic nerve lesions.   
**Note:** There are multiple retinal conditions that would be considered
covered indications that may not be listed below. For a complete listing of
covered diagnoses, please refer to the Local Coverage Article: Billing and
Coding: Electroretinography (ERG), A56672 for all billing and coding
information.

    * Toxic retinopathies, including those caused by intraocular metallic foreign bodies, Vigabatrin and Chlorpromazine
    * Diabetic retinopathy
    * Retinal vascular disease (e.g., Central Retinal Artery Occlusion [CRAO], Central Retinal Vein Occlusion [CRVO], Branch Vein Occlusion [BVO], and sickle cell retinopathy)
    * Autoimmune retinopathies (e.g., Cancer Associated Retinopathy [CAR], Melanoma Associated Retinopathy [MAR], and Acute Zonal Occult Outer Retinopathy [AZOOR])
    * Retinal detachment
    * Assessment of retinal function after trauma (e.g., vitreous hemorrhage, dense cataracts, and other conditions where the fundus cannot be visualized)
    * Retinitis pigmentosa and related hereditary degenerations
    * Retinitis punctata albescens
    * Leber's congenital amaurosis
    * Choroideremia
    * Gyrate atrophy of the retina and choroid
    * Goldman-Favre syndrome
    * Congenital stationary night blindness
    * X-linked juvenile retinoschisis
    * Achromatopsia
    * Cone dystrophy
    * Disorders mimicking retinitis pigmentosa
    * Usher Syndrome
    * Retinal Dystrophies (e.g., Stargardt's disease, Fundus Flavimaculata, North Carolina macular dystrophy, Best's Vitelliform dystrophy, Sorsby's macular dystrophy)  


  2. To detect chloroquine (Aralen) and hydroxychloroquine (Plaquenil) toxicity (mfERG) per AAO guidelines, which does not recommend mfERG for routine primary screening, but can provide objective confirmation of suspected visual loss.

  
**Limitations**  
  
The following is considered not reasonable and necessary and therefore will be
denied:

  1. The use of ERG for glaucoma (either diagnosis or management) is considered experimental and investigational as the available published clinical evidence does not support clinical value. Therefore, the use of ERG, (all forms: ERG, fERG, mfERG, PERG, etc.) for glaucoma is non-covered and will be denied as not reasonable and necessary.

  
**Place of Services (POS)**

For additional information on services performed in an Independent Diagnostic
Testing Facility (IDTF), please refer to Local Coverage Determination (LCD)
L35448 Independent Diagnostic Testing Facility (IDTF) and Local Coverage
Article A53252 Independent Diagnostic Testing Facility (IDTF).

**Notice:** Services performed for any given diagnosis must meet all of the
indications and limitations stated in this policy, the general requirements
for medical necessity as stated in CMS payment policy manuals, any and all
existing CMS national coverage determinations, and all Medicare payment rules.
Refer to the Local Coverage Article: Billing and Coding: Electroretinography
(ERG), A56672, for applicable CPT/HCPCS codes and diagnosis codes.

  
**Provider Qualifications**

  1. Diagnostic ERG testing must be performed under the general supervision of and interpreted by a qualified physician.

    * Qualified physicians must possess evidence of knowledge, training, and expertise to perform and interpret these tests. This training and expertise must have been acquired within the framework of an accredited school, residency or fellowship program.
    * Please refer to CMS IOM Pub. 100-02, Chapter 15, Section 80 for the definition of General Supervision.

The redetermination process may be utilized for consideration of services
performed outside of the reasonable and necessary requirements in this LCD.

Please refer to the "History/Background and/or General Information" section
for general information on ERG including full field ERG, focal ERG, multi-
focal ERG, and pattern ERG.  
  
Multiple sources of literature (Bach et al. [2013]; Barrett et al. [2014]; CK
et al. [2011]; Creel; Hood et al. [2012]; Incesu [2013]; International Society
for Clinical Electrophysiology of Vision [ISCEV]; Jacobs; John et al. [2009];
Kumar et al.; Maa et al. [2016]; Marmor et al. [2016]; McBain et al. [2007];
McCulloch et al. [2015]; Perlman; Whatham et al. [2014]) were submitted for
consideration. These were mostly descriptive of how ERG should be performed,
the history of the testing procedures involved with ERG and sources for the
"Covered Indications" section.  
  
This is a new LCD for Novitas JH and JL developed as a national MAC LCD
workgroup collaboration based on information from data analysis revealing that
a significant percentage of the diagnoses reported on ERG claims contained
some form of a glaucoma diagnosis. These findings were not consistent with
current literature and guideline recommendations for ERG use.  
  
The following is a summary of the evidence for exclusion of glaucoma-related
diagnoses for testing by ERG (except glaucomatous optic atrophy):  
  
A) Evidence-Based Guidelines

  * The American Academy of Ophthalmology (AAO) Glaucoma Preferred Practice Pattern Panel of 2014-2015 included reviewers from the Ophthalmic Technology Assessment Committee Glaucoma Panel, Practicing Ophthalmologists Advisory Committee for Education and reviewers from the American Academy of Family Physicians, American College of Physicians, American College of Surgeons, American Glaucoma Society, American Ophthalmological Society, American Society of Cataract and Refractive Surgery, Association of University Professors of Ophthalmology, Glaucoma Research Foundation, National Eye Institute, plus multiple other international and national societies. The Preferred Practice Pattern Panel did not include ERG in their diagnostic testing recommendations. The diagnostic tests included by the panel are central corneal thickness (CCT) measurement, visual field evaluation and optic nerve head (ONH) and retinal nerve fiber layer (RNFL) imaging. There are 598 references listed for Primary Open-Angle Glaucoma and 230 references listed for Primary Open-Angle Glaucoma Suspect with ratings based on the Scottish Intercollegiate Guideline Network and the GRADE group within the documents.

  * In addition, the American Optometric Association (AOA), in their clinical practice guideline on the care of the patient with open-angle glaucoma (last revised in 2010), did not include ERG in their diagnostic testing recommendations.

  * Jampel, et al. conducted a literature review for an ophthalmic technology assessment of visual function in glaucoma, which was published by the AAO in 2011, and concluded that advances in technology (including ERG) have yet to produce definitive guidance in the diagnosis of glaucoma or its progression over time and further research on an objective measure of visual function is needed. Listed were 81 references with a grading system and strength of evidence.

B) Systematic Review

  * Lai, et al. (2007) conducted a systematic review for the clinical applications of mfERG. The conclusions were mfERG is not very reliable in the detection and monitoring of functional loss caused by glaucoma, second-order kernel mfERG responses are not very useful in investigating glaucomatous damage, the use of mfERG s-wave in assessing glaucomatous damage remains uncertain, and the sensitivity of mfERG in detecting retinal dysfunction in ocular hypertension (OHT) patients remains questionable. Listed were 329 references with limitations of the studies discussed within the review article.

C) Observational Studies

  * Bach, et al. (2006), in a prospective cohort study conducted in Germany, followed 54 subjects with OHT for at least three years (median follow-up of 8.2 years) using PERG and visual field testing at six month intervals. Glaucoma developed in five subjects. The median age of the subjects was 52 years. Pressure-lowering treatment (eye drops, laser, laser + eye drops and trabeculectomy) was received by 82% of the subjects at some point during the study. The study results found that one year before conversion, the receiver-operating characteristic (ROC) area of the PERG ratio was 0.78. At a threshold of 1.06, this corresponded to a sensitivity of 80%, a specificity of 71%, a positive predictive value of 23%, and a negative predictive value of 97%. The study conclusion was PERG can help to predict stability or progression to glaucoma in OHT at least one year prior to conversion.

  * Bode, et al. (2011) was a continuation of the Bach, et al. (2006) prospective cohort study in Germany. The study followed 64 subjects with OHT for at least three years (mean of 10.3 years). The median age of the subjects was 60.6 years. The study conclusion was PERG, especially the PERG ratio, detected glaucoma patients four years before visual field changes occurred, with a sensitivity of 75% and specificity of 76%.

    * The quality of evidence for these studies is low due to the small study sizes, problems with interpretation due to the fact that treatment probably distorted the natural course, and the studies were not generalizable to a Medicare population.

  * Banitt, et al. (2013), in a prospective cohort study, followed 107 glaucoma suspect subjects for at least four years using PERG, optical coherence tomography (OCT) of the RNFL and standard automated perimetry testing at six month intervals. The mean age of the subjects was 56.1 +/- 10.1 years. A total of 56 subjects received pressure-lowering medications at some point during the study. The study conclusion was PERG signal anticipates an equivalent loss of OCT signal by several years. The quality of evidence for this study is low due to the small study size, shifts in intraocular pressure (IOP) could have led to overestimation or underestimation of PERG loss rates, and the study was not generalizable to a Medicare population.

  * Jafarzadehpour, et al. (2013), in a prospective case control study in Iran, tested 20 glaucoma suspects, 15 early primary open angle glaucoma (POAG) and 16 normal control subjects using PERG. Responses were recorded to 0.8 degree and 16 degree black and white checkerboard stimuli. One of the exclusion criteria for the study was age greater than 65 years. The study conclusion was PERG may detect retinal ganglion cell (RGC) dysfunction (increased latency) before cell death (decreased amplitude) occurs. The quality of evidence for this study is low due to the small study size and the study was not generalizable to a Medicare population.

  * Nesher and Trick (1991) performed a retrospective analysis on the transient and steady-state PERG recorded from 205 subjects. The subjects were divided into 42 with glaucoma, 13 with senile dementia of Alzheimer's type, 58 with diabetes mellitus (27 without retinopathy and 31 with retinopathy) and 92 control subjects. The mean age of the glaucoma subjects was 56.8 +/- 9.8 years. The analysis found inconsistency in the glaucoma subjects' results when compared to a study by Holder published in 1989. The study conclusion was a recommendation to record the PERG under both transient and steady-state conditions to optimize the clinical utility of the procedure. The quality of evidence for this study is low due to the small study size, the results for the glaucoma patients was inconsistent with a previous study, and the study was not generalizable to a Medicare population.

  * Tafreshi, et al. (2010), in a cross-sectional study, performed PERG, standard automated perimetry (SAP), short-wavelength automated perimetry (SWAP), and frequency-doubling technology (FDT) on 42 healthy subjects and 54 glaucoma subjects. The average age of the healthy subjects was 63.6 years and the average age of the glaucoma subjects was 70.4 years. The study conclusions were the diagnostic accuracy of PERG amplitude was similar to SAP and SWAP, but worse than FDT. Also, PERG may hold some advantage over psychophysical testing because of its largely objective nature. The quality of the evidence is low due to the small study size and the study did not demonstrate an improvement in health outcomes for the Medicare population.

  * Ventura, et al. (2005), in a cross-sectional study, performed PERG, SAP, and vertical cup-to-disc ratios (C/D) on 200 glaucoma suspect (GS) subjects, 42 early manifestation glaucoma (EMG) subjects and 114 control subjects. The mean age of the GS and EMG subjects was 57 +/- 13 years. The mean age of the control subjects was 46.4 +/- 18.2 years. The study conclusion was the correlation between PERG abnormality and known risk factors for glaucoma indicates that PERG has a predictive potential for the development or progression of glaucoma, or both. The quality of evidence for this study is low due to the study was not generalizable to a Medicare population.

  * Ventura, et al. (2013), in a prospective cohort study, followed 59 glaucoma suspect subjects for 5.7 +/- 1.4 years using PERG and SAP two times per year. The age of the subjects was not reported in the study. None of the subjects received intraocular pressure-lowering medications at any point during the study. The study conclusion was that it remains to be established whether PERG progression has predictive value for developing visual dysfunction. The quality of evidence for this study is low due to the small study size and the study was not generalizable to a Medicare population.

The use of ERG to diagnose loss of retinal function or distinguish between
retinal lesions and optic nerve lesions is supported in the literature for a
wide variety of conditions (e.g. toxic, diabetic and autoimmune retinopathies,
retinal vascular disease, retinal detachment and/or trauma, hereditary or
congenital retinal diseases).  
  
The quality of evidence for the observational studies for ocular hypertension,
glaucoma suspect and glaucoma is low due to the small study sizes, the studies
were not generalizable to a Medicare population, and the studies did not
demonstrate an improvement in health outcomes for the Medicare population.
Evidence based guidelines from the American Academy of Ophthalmology (AAO) and
the American Optometric Association (AOA) did not support the use of ERG for
these conditions. Based on the weak strength of study evidence and the absence
of sound data to support the clinical utility of ERG for ocular hypertension,
glaucoma suspect, or glaucoma, there is little evidence to support the use of
ERG in the Medicare population for these conditions.  
  
 **Note:** This analysis used the American College of Physicians (ACP)
Guideline Grading System as the basis for grading the quality of evidence and
analyzing the evidence.